Equities

Ribomic Inc

4591:TYO

Ribomic Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)88.00
  • Today's Change1.00 / 1.15%
  • Shares traded65.70k
  • 1 Year change-45.68%
  • Beta1.1375
Data delayed at least 20 minutes, as of Jun 07 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-1.02bn
  • Incorporated2003
  • Employees25.00
  • Location
    Ribomic Inc6F, Shirokanedai Usui Bldg.3-16-13, ShirokanedaiMINATO-KU 108-0071JapanJPN
  • Phone+81 334403303
  • Fax+81 334403729
  • Websitehttps://www.ribomic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PhoenixBio Co Ltd1.72bn26.38m1.93bn65.00135.091.0858.841.133.553.55409.59446.270.59831.286.80--0.9201-4.041.31-5.2869.6765.881.54-6.973.99--0.2871---19.246.91-94.65---9.96--
Modalis Therapeutics Corp0.00-2.32bn2.62bn37.00--2.33-----72.46-72.460.0029.590.00----0.00-103.95-29.19-112.89-30.02-------597.359.75--0.2638---100.00--11.50--135.50--
Muromachi Chemicals Inc6.12bn216.69m2.79bn205.0012.741.297.940.455653.4553.451,503.34527.871.203.833.7529,862,370.004.23--6.84--28.31--3.54--1.4526.200.4483--10.74---43.83------
D.Western Therapeutics Institute Inc443.18m-1.04bn2.94bn21.00--3.05--6.63-32.29-32.2913.8429.840.17840.4723.1021,103,950.00-42.16-13.06-45.11-14.3691.3294.29-236.36-72.5111.65--0.509---4.407.90-89.07--7.08--
Atect Corp3.18bn-244.35m3.14bn96.00--1.789.090.9891-55.27-55.27718.38398.840.58953.306.85---4.540.7132-6.410.971843.4047.04-7.691.320.6992--0.590284.767.231.45-253.71---23.490.00
Ribomic Inc0.00-1.02bn3.29bn25.00--0.9554-----28.70-28.700.0094.200.00-------25.19-30.52-26.34-31.71-------1,777.8422.49-------100.00--38.04--4.42--
Human Metabolome Technologies Inc1.34bn285.75m3.83bn57.0013.411.9910.362.8648.3148.31226.62326.170.564317.823.8023,500,000.0012.04--15.43--63.89--21.33--3.84124.760.1061--6.21--6.71------
Kubota Pharmaceutical Holdings Co Ltd39.74m-1.39bn4.05bn12.00--1.73--101.99-24.82-24.820.71141.580.01180.381526.893,312,000.00-41.32-36.51-45.53-39.4772.88---3,492.38-13,528.878.97--0.0555--383.24--26.11--24.38--
FunPep Co Ltd676.00k-760.40m4.06bn15.00--1.72--6,002.03-31.52-31.520.02890.560.0002--3.3945,066.67-26.86-27.10-28.42-28.75-----112,484.90-815.8217.27-1,006.150.00---50.33-72.8020.39---13.14--
Perseus Proteomics Inc100.40m-1.10bn4.12bn24.00--2.65--41.00-93.74-93.748.52117.150.04713.358.55---51.85-41.34-54.94-43.4387.3391.72-1,100.04-891.2612.77------6.58-18.31-40.34--60.30--
Delta-Fly Pharma Inc0.00-1.43bn4.34bn11.00--3.52-----197.24-197.240.00149.780.00-------120.07-67.70-141.25-72.02-----------243.15---------7.57---9.04--
BrightPath Biotherapeutics Co Ltd72.00k-1.17bn4.40bn32.00--4.48--61,088.34-18.30-18.300.001113.840.00005--2.36---79.69-51.56-87.69-54.3275.0068.63-1,622,336.00-22,321.82---435.390.1031---98.64-78.4721.37---46.55--
Renascience Inc194.17m-258.34m4.61bn3.00--2.87--23.77-20.32-20.3215.27126.400.089-------11.84---12.49--85.31---133.05------0.1814--93.11--23.07------
Immuno-Biological Laboratories Co., Ltd.816.70m186.69m4.69bn60.0025.143.71--5.7520.0520.0587.69135.860.5350.93584.53--12.23-13.9714.68-16.3963.3457.7322.86-39.233.65--0.1572--2.780.8924164.44------
OncoTherapy Science, Inc.610.12m-1.29bn4.79bn60.00--12.31--7.85-6.09-6.092.871.620.5139.087.69---108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
Data as of Jun 07 2024. Currency figures normalised to Ribomic Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.